IL145584A0 - Nmda nr2b antagonists for treatment - Google Patents

Nmda nr2b antagonists for treatment

Info

Publication number: IL145584A0
Authority: IL; Israel
Prior art keywords: treating; treatment; depression; neurodegeneration; nr2b antagonists
Prior art date: 2000-10-02

Application number

IL14558401A

Other languages

English (en)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-02

Filing date

2001-09-24

Publication date

2002-06-30

2001-09-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-06-30 Publication of IL145584A0 publication Critical patent/IL145584A0/xx

Links

HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title abstract 2
239000005557 antagonist Substances 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
230000004770 neurodegeneration Effects 0.000 abstract 2
201000004569 Blindness Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
206010011878 Deafness Diseases 0.000 abstract 1
208000001089 Multiple system atrophy Diseases 0.000 abstract 1
101710138657 Neurotoxin Proteins 0.000 abstract 1
208000005374 Poisoning Diseases 0.000 abstract 1
208000005793 Restless legs syndrome Diseases 0.000 abstract 1
102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
208000031889 Vascular Depression Diseases 0.000 abstract 1
208000001407 Vascular Headaches Diseases 0.000 abstract 1
230000010370 hearing loss Effects 0.000 abstract 1
231100000888 hearing loss Toxicity 0.000 abstract 1
208000016354 hearing loss disease Diseases 0.000 abstract 1
239000002581 neurotoxin Substances 0.000 abstract 1
231100000618 neurotoxin Toxicity 0.000 abstract 1
231100000572 poisoning Toxicity 0.000 abstract 1
230000000607 poisoning effect Effects 0.000 abstract 1
230000004393 visual impairment Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Quinoline Compounds (AREA)

IL14558401A 2000-10-02 2001-09-24 Nmda nr2b antagonists for treatment IL145584A0 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US23777000P	2000-10-02	2000-10-02

Publications (1)

Publication Number	Publication Date
IL145584A0 true IL145584A0 (en)	2002-06-30

Family

ID=22895086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14558401A IL145584A0 (en)	2000-10-02	2001-09-24	Nmda nr2b antagonists for treatment

Country Status (13)

Country	Link
US (3)	US7019016B2 (de)
EP (1)	EP1199068B1 (de)
JP (1)	JP2002161052A (de)
KR (1)	KR100430539B1 (de)
AT (1)	ATE350103T1 (de)
AU (1)	AU7730401A (de)
CA (1)	CA2357929A1 (de)
DE (1)	DE60125681T2 (de)
ES (1)	ES2276750T3 (de)
HU (1)	HUP0104018A3 (de)
IL (1)	IL145584A0 (de)
NZ (1)	NZ514554A (de)
ZA (1)	ZA200107951B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080207755A1 (en) *	2000-05-31	2008-08-28	Pfizer Inc	Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en)	1999-06-10	2007-01-16	Pfizer Inc.	Alpha2delta ligands for fibromyalgia and other disorders
IL145584A0 (en) *	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment
JP2004537526A (ja) *	2001-06-12	2004-12-16	メルク　エンド　カムパニー　インコーポレーテッド	片頭痛の治療又は予防用ｎｒ２ｂ受容体拮抗薬
US6743921B2 (en) *	2002-01-24	2004-06-01	Dsm Catalytica Pharmaceuticals, Inc.	Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US6855735B2 (en) *	2002-03-20	2005-02-15	Temple University Of The Commonwealth System Of Higher Education	Ketamine treatment of restless legs syndrome
NZ540591A (en) *	2002-12-13	2008-03-28	Warner Lambert Co	Pregabalin derivatives for the treatment of fibromyalgia and other disorders
SE526255C2 (sv) *	2003-03-14	2005-08-09	Sandvik Intellectual Property	Verktyg och indexerbart skär för finsvarvning av rotationssymmetriska spår i arbetsstycken
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
EP2278999B1 (de)	2008-04-21	2025-01-29	Dompé farmaceutici S.p.A.	Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
JP2011520815A (ja) *	2008-05-09	2011-07-21	エモリー・ユニバーシテイ	精神神経障害治療のためのｎｍｄａ受容体拮抗薬
US8496957B2 (en) *	2008-07-21	2013-07-30	Otonomy, Inc	Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8648198B2 (en)	2011-01-19	2014-02-11	Cold Spring Harbor Laboratory	Phenylethanolamine-based NMDA receptor antagonists
WO2012098000A1 (en) *	2011-01-20	2012-07-26	Merz Pharma Gmbh & Co. Kgaa	Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
IL234638A0 (en) *	2014-09-14	2014-12-02	Yeda Res & Dev	NMDA receptor antagonists for the treatment of Gaucher disease
KR101705448B1 (ko)	2015-05-18	2017-02-09	허동길	애완동물용 물통
US11207307B2 (en)	2016-06-16	2021-12-28	Azurity Pharmaceuticals, Inc.	Composition and method for proton pump inhibitor suspension
US10751333B1 (en)	2019-07-16	2020-08-25	Cutispharma, Inc.	Compositions and kits for omeprazole suspension
US11633478B2 (en)	2019-07-16	2023-04-25	Azurity Pharmaceuticals, Inc.	Compositions and kits for Omeprazole suspension
US20240041853A1 (en) *	2020-12-04	2024-02-08	Novartis Ag	Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5710168A (en) *	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
MX9701282A (es) *	1994-08-18	1997-05-31	Pfizer	Fenoles neuroprotectores.
DK0843661T3 (da) *	1995-08-11	2002-07-22	Pfizer	(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
ZA9610736B (en) *	1995-12-22	1997-06-27	Warner Lambert Co	2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) *	1995-12-22	1997-06-24	Warner Lambert Co	4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
AU1463997A (en) *	1995-12-22	1997-07-17	Acea Pharmaceuticals, Inc.	Subtype-selective nmda receptor ligands and the use thereof
EP0787493A1 (de) *	1996-02-03	1997-08-06	F. Hoffmann-La Roche Ag	Tetrahydroisochinolin-Derivate
KR200153170Y1 (ko) *	1997-08-30	1999-08-02	정몽규	볼죠인트구조
GB9804886D0 (en) *	1998-03-06	1998-04-29	Merck Sharp & Dohme	Therapeutic combination
GB9804885D0 (en) *	1998-03-06	1998-04-29	Merck Sharp & Dohme	Therapeutic combination
PE20000728A1 (es) *	1998-06-26	2000-08-21	Cocensys Inc	Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
US20010007872A1 (en) *	1998-10-01	2001-07-12	Frank S. Menniti	Method of treating acute, chronic and/or neuropathic pain
IL145584A0 (en)	2000-10-02	2002-06-30	Pfizer Prod Inc	Nmda nr2b antagonists for treatment

2001
- 2001-09-24 IL IL14558401A patent/IL145584A0/xx unknown
- 2001-09-27 ZA ZA200107951A patent/ZA200107951B/xx unknown
- 2001-09-28 AT AT01308295T patent/ATE350103T1/de not_active IP Right Cessation
- 2001-09-28 AU AU77304/01A patent/AU7730401A/en not_active Abandoned
- 2001-09-28 ES ES01308295T patent/ES2276750T3/es not_active Expired - Lifetime
- 2001-09-28 DE DE60125681T patent/DE60125681T2/de not_active Expired - Fee Related
- 2001-09-28 CA CA002357929A patent/CA2357929A1/en not_active Abandoned
- 2001-09-28 EP EP01308295A patent/EP1199068B1/de not_active Expired - Lifetime
- 2001-09-29 KR KR10-2001-0060916A patent/KR100430539B1/ko not_active Expired - Fee Related
- 2001-10-01 NZ NZ514554A patent/NZ514554A/en unknown
- 2001-10-01 HU HU0104018A patent/HUP0104018A3/hu unknown
- 2001-10-02 US US09/969,317 patent/US7019016B2/en not_active Expired - Fee Related
- 2001-10-02 US US09/969,318 patent/US6958351B2/en not_active Expired - Fee Related
- 2001-10-02 JP JP2001306254A patent/JP2002161052A/ja active Pending
2004
- 2004-04-09 US US10/821,526 patent/US20040192763A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60125681T2 (de)	2007-10-04
AU7730401A (en)	2002-04-11
KR100430539B1 (ko)	2004-05-10
ZA200107951B (en)	2003-04-29
KR20020027203A (ko)	2002-04-13
NZ514554A (en)	2004-10-29
US20040162312A1 (en)	2004-08-19
CA2357929A1 (en)	2002-04-02
US7019016B2 (en)	2006-03-28
US20040192763A1 (en)	2004-09-30
JP2002161052A (ja)	2002-06-04
HU0104018D0 (en)	2001-12-28
HUP0104018A2 (hu)	2002-07-29
HUP0104018A3 (en)	2004-04-28
ATE350103T1 (de)	2007-01-15
US20020072538A1 (en)	2002-06-13
EP1199068B1 (de)	2007-01-03
EP1199068A3 (de)	2003-06-18
EP1199068A2 (de)	2002-04-24
DE60125681D1 (de)	2007-02-15
US6958351B2 (en)	2005-10-25
ES2276750T3 (es)	2007-07-01

Publication	Publication Date	Title
ZA200107951B (en)	2003-04-29	NMDA NR2B antagonists for treatment.
AU6110301A (en)	2001-11-12	Diagnostics and therapeutics for macular degeneration-related disorders
WO2005079756A3 (en)	2005-09-22	Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2006119349A3 (en)	2007-05-18	Choroid and retinal imaging and treatment system
WO2003096983A3 (en)	2005-01-13	Method of treating dyslipidemic disorders
WO2003020212A3 (en)	2004-02-19	Treatment for central nervous system disorders
WO2006105403A3 (en)	2007-03-15	Treatment of eye disorders with sirtuin modulators
ZA200300411B (en)	2004-01-26	Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
TW200738270A (en)	2007-10-16	Method of treating depression using a TNFα antibody
EP2258382A3 (de)	2014-05-14	Amylin und Amylin-Antagonisten zur Behandlung psychiatrischer Erkrankungen und Störungen
EP2023926A4 (de)	2010-08-04	Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
ATE492279T1 (de)	2011-01-15	Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
WO2006127987A3 (en)	2008-04-17	Treatment of eye disorders with sirtuin modulators
WO2002074327A3 (en)	2002-12-12	Compositions and methods for treating gonadotrophin related illnesses
IL157465A0 (en)	2004-03-28	Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
ZA200208492B (en)	2003-05-15	Game server, game machine under control of the server, and game control method.
IL148071A0 (en)	2002-09-12	Method for treatment of symptoms of central nervous system disorders
IL213523A0 (en)	2011-07-31	Compositions comprising blood group antigens
PL1694354T3 (pl)	2009-12-31	Sposób zapobiegania i leczenia cukrzycy za pomocą neurturyny
EP1186232A4 (de)	2004-11-10	'knockout' tiere, denen das lkb1-gen fehlt
ZA200309733B (en)	2004-09-29	Method and apparatus for distributing treatment agents.
MXPA03006607A (es)	2003-09-22	Metodo combinado para tratar trastornos dependientes de hormonas.
WO2006138127A3 (en)	2007-05-03	Botulinum toxin and the treatment of primary disorders of mood and affect
TW200502234A (en)	2005-01-16	Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
YU89103A (sh)	2006-08-17	Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a